Share on StockTwits
 

Nu Skin Enterprises (NYSE:NUS)‘s stock had its “buy” rating reaffirmed by stock analysts at Deutsche Bank in a report issued on Wednesday, AnalystRatingsNetwork.com reports.

The analysts wrote, “currently discounting a significant decline in the company’s Chinesebusiness,” creating an attractive entry point. He also pointed at a “pristine” balance sheet and fundamentals outside of China which “are still among best in class across the CPG universe.”

Shares of Nu Skin Enterprises (NYSE:NUS) traded up 6.15% on Wednesday, hitting $82.15. 5,355,612 shares of the company’s stock traded hands. Nu Skin Enterprises has a 52-week low of $37.93 and a 52-week high of $140.50. The stock’s 50-day moving average is $128.6 and its 200-day moving average is $104.3. The company has a market cap of $4.886 billion and a price-to-earnings ratio of 15.84.

A number of other firms have also recently commented on NUS. Analysts at Zacks downgraded shares of Nu Skin Enterprises from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday. They now have a $101.80 price target on the stock. Separately, analysts at Merrill Lynch downgraded shares of Nu Skin Enterprises from a “buy” rating to a “neutral” rating in a research note to investors on Friday, January 17th. They now have a $94.00 price target on the stock, down previously from $147.00. Finally, analysts at Bank of America Corp. downgraded shares of Nu Skin Enterprises from a “buy” rating to a “neutral” rating in a research note to investors on Friday, January 17th. They now have a $94.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $107.60.

Nu Skin Enterprises, Inc is a global direct selling company with operations in 53 markets worldwide. The Company develops and distributes anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands, respectively.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.